25 Multiple Myeloma Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Multiple Myeloma Studies in Chicago

NCT07656584Recruiting

Implementation of Communication Disability Collection and Accommodations in Primary Care Settings

This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disa...

Chicago, ILNA126,870 participantsNYU Langone Health

View Study Details

NCT02735707Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

Chicago, ILPHASE320,000 participantsUMC Utrecht

View Study Details

NCT06986148Recruiting

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring ...

Chicago, ILNA2,000 participantsAnn & Robert H Lurie Children's Hospital of Chicago

View Study Details

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

Chicago, ILPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT07053436Recruiting

Horizon Two: HR NDMM (MMRC-100)

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigatio...

Chicago, ILPHASE2300 participantsMultiple Myeloma Research Consortium

View Study Details

NCT03816345Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, an...

Chicago, ILPHASE1300 participantsNational Cancer Institute (NCI)

View Study Details

NCT05201781Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...

Chicago, ILPHASE4295 participantsJanssen Research & Development, LLC

View Study Details

NCT04643002Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...

Chicago, ILPHASE1258 participantsSanofi

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Chicago, ILPHASE1246 participantsBeiGene

View Study Details

NCT05862012Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM)....

Chicago, ILPHASE1200 participantsIchnos Sciences SA

View Study Details

NCT04803201Recruiting

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with perip...

Chicago, ILPHASE2170 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT05294042Recruiting

Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities

The purpose is to study a model of mental health navigation for African American and Latinx children (0-14 years) in high poverty urban communities focused on reducing key parental attitudinal barrier...

Chicago, ILNA154 participantsUniversity of Illinois at Chicago

View Study Details

NCT06055439Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

Chicago, ILPHASE1135 participantsChimeric Therapeutics

View Study Details

NCT07096778Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come b...

Chicago, ILPHASE2100 participantsCellCentric Ltd.

View Study Details

NCT04483206Recruiting

Personalized Autologous Transplant for Multiple Myeloma

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in ...

Chicago, ILPHASE190 participantsEmory University

View Study Details

NCT05789303Recruiting

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma t...

Chicago, ILPHASE283 participantsUniversity of Chicago

View Study Details

NCT05979090Recruiting

Mastery Learning in Communication Skills

The goal of this study is to determine whether mastery learning in communication skills can improve skills in a simulated environment and have translational improvements in outcomes. The main question...

Chicago, ILNA80 participantsHeather Ballard

View Study Details

NCT06544499Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...

Chicago, ILPHASE369 participantsargenx

View Study Details

NCT05344833Recruiting

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)...

Chicago, ILPHASE250 participantsUniversity of Illinois at Chicago

View Study Details

NCT05192122Recruiting

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients....

Chicago, ILPHASE150 participantsUniversity of Illinois at Chicago

View Study Details

NCT06401356Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

Chicago, ILPHASE350 participantsNovartis Pharmaceuticals

View Study Details

NCT05705024Recruiting

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of...

Chicago, ILPHASE238 participantsUniversity of Illinois at Chicago

View Study Details

NCT05579392Recruiting

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and aff...

Chicago, ILNA30 participantsRush University Medical Center

View Study Details

NCT06270888Recruiting

Hypofractionation (Radiation) Trial for Multiple Myeloma

This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiat...

Chicago, ILPHASE130 participantsUniversity of Chicago

View Study Details

NCT05040178Recruiting

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®....

Chicago, IL20 participantsRECORDATI GROUP

View Study Details

About Multiple Myeloma Clinical Trials in Chicago

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 25 multiple myeloma clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 152,128 participants. Research is being sponsored by NYU Langone Health, UMC Utrecht, Ann & Robert H Lurie Children's Hospital of Chicago and 17 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Chicago — FAQ

Are there multiple myeloma clinical trials in Chicago?

Yes, there are 25 multiple myeloma clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 25 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated September 1, 2026 from ClinicalTrials.gov